Prostate questions often come up when men consider testosterone treatment later in life. The PSA blood test can be part of that conversation, but it does not give a simple yes-or-no answer about cancer.
A useful discussion separates screening decisions, existing urinary symptoms, and monitoring during treatment. Your age, history, medications, and preferences all belong in the conversation with a clinician.
- PSA can rise for reasons other than cancer.
- Screening should include a discussion of benefits and harms.
- Ask who reviews changes and coordinates further evaluation.
What PSA can and cannot tell you
PSA is a protein made by prostate cells. Cancer can raise its blood level, but so can noncancerous conditions such as enlargement or inflammation. A single threshold cannot perfectly separate people with cancer from people without it. A higher result needs context and may lead to further evaluation.
Tell the clinician about urinary symptoms, prior PSA results, family history, and medicines such as finasteride or dutasteride, which can affect interpretation. Keep previous reports so the clinician can see a trend. Do not compare your number with a friend’s result and assume the same advice applies.
Screening has benefits and tradeoffs
Screening can identify a concern before symptoms appear, but it can also lead to false alarms, further procedures, or discovery of a cancer that would not have caused harm. The National Cancer Institute describes why the decision should include an informed discussion of benefits and harms.
Age and individual risk influence that discussion. A TRT advertisement is not a prostate-screening recommendation. Ask your clinician which decisions apply to you, why a test is being ordered, and what different results would mean before the blood draw.
How this connects to testosterone care
The Endocrine Society recommends assessment of prostate risk where appropriate before treatment and follow-up during care. Certain findings require evaluation before testosterone is started. Its guidance also describes circumstances during treatment in which urology consultation is appropriate; those are referral signals, not a cancer diagnosis.
Ask who compares your result with the baseline and who arranges any additional evaluation. Our TRT after 50 guide explains why age alone should not determine treatment. The discussion should include the reason for TRT and the plan for reviewing benefit and risk.
Questions worth bringing
Ask whether the test is for screening, investigation of a symptom, or monitoring a known condition. Ask which prior records matter and whether any medication changes interpretation. If the result changes, ask what happens next and when you should expect an explanation.
Keep prostate monitoring alongside the other parts of care. Our hematocrit guide covers a different laboratory measure, while the monitoring overview connects the pieces. No single normal result establishes that a treatment is suitable indefinitely.
Sources & reading notes
Provider pages describe advertised services, not independently verified outcomes. Prices and eligibility may change. Checked September 20, 2026.